Market Cap
$11.6B
MDGL
MADRIGAL PHARMACEUTICALS, INC.
$499.40 ▼ -0.06%
Prev close $499.71Market cap$11.6B
ConsensusStrong Buy
12-mo target$682.11 (+36.6%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)29 New Institutional Positions21 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on MDGL right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
50 funds
Inst. Value
$11.1B
Inst. Activity
29 buys / 21 sells
Insider Activity
$0.00 buy / $7.9M sell
Insider Net $
-$7.9M
SEC Reports
8
Press Releases
1
Price chart 30d -8.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 16, 2026 other
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL),
Sep 11, 2026 Insider
Sibold William John sold 60 shares
President and CEO @ $533.09 ($32.0K)
Sep 11, 2026 Insider
Sibold William John sold 218 shares
President and CEO @ $535.94 ($116.8K)
Sep 11, 2026 Insider
Aug 12, 2026 SEC Sibold William John sold 368 shares
President and CEO @ $541.64 ($199.3K)
Madrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., a top R&D executive from Johnson & Johnson, to its Board o
8-K — Impact 3/10
Madrigal Pharmaceuticals reported Q2 2026 Rezdiffra net sales of $364.3M, up 71% YoY, beating consensus revenue estimate
8-K — Impact 7/10
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
401,708 shares ($215.7M)
Jun 30, 2026 Inst.
FMR LLC — TRIM
356,201 shares ($191.3M)
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 24 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | Citigroup | INITIATE | Buy | 55% |
| Aug 4, 2026 | Wolfe Research | UPGRADE | Outperform | 52% |
| Aug 3, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Jul 29, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Jul 27, 2026 | Wells Fargo | INITIATE | Overweight | 54% |
| Jun 11, 2026 | B of A Securities | MAINTAIN | Neutral | 54% |
| May 13, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| May 7, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| May 7, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| May 6, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 16 | 2 | 0 | 0 | 92% | |
| Aug 1, 2026 | 5 | 16 | 3 | 0 | 0 | 88% | |
| Jul 1, 2026 | 5 | 15 | 3 | 0 | 0 | 87% | |
| Jun 1, 2026 | 5 | 15 | 3 | 0 | 0 | 87% | |
| May 1, 2026 | 5 | 15 | 3 | 0 | 0 | 87% | |
| Apr 1, 2026 | 5 | 15 | 3 | 0 | 0 | 87% | |
| Mar 1, 2026 | 5 | 15 | 3 | 0 | 0 | 87% | |
| Feb 1, 2026 | 5 | 16 | 3 | 0 | 0 | 88% |
Price targets
Where 18 covering analysts think MDGL trades over the next 12 months.
$682.11 +36.6% upside Strong Buy
Current$499.40 Low$543.00 Median$661.00 High$962.00 18 analysts
$543.00$962.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 2 bullish, 0 bearish, 0 mixed, 6 neutral · avg impact 4.0/10.Plus 1 press releases.
NEUTRAL8-K3/10
Madrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., a top R&D executive from Johnson & Joh
Aug 12, 2026
BULLISH8-K7/10
Madrigal Pharmaceuticals reported Q2 2026 Rezdiffra net sales of $364.3M, up 71% YoY, beating consen
Jul 30, 2026
NEUTRALCLUSTER3/10
Two Madrigal insiders (Director Levy and CMO Soergel) sold a combined $456K in open-market transacti
May 22, 2026
BULLISH8-K7/10
Madrigal Pharmaceuticals reported Q1 2026 Rezdiffra net sales of $311.3M (+127% YoY), beating consen
May 6, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 16, 2026
other
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering
Sep 10, 2026
Clinical Trial
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Sep 10, 2026
clinical_trial_readout
T-90d Trial Readout: Resmetirom (Phase 3)
Trial: A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOM
Sep 7, 2026
dark_pool
Dark Pool: MDGL — 0.3M shares, 18,897 trades
Week starting 2026-09-07. Total ATS volume: 321,892 shares across 18,897 trades.
Sep 2, 2026
clinical_trial_readout
T-90d Trial Readout: Resmetirom (Phase 3)
Trial: A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOM
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.09 | $-1.38–$-0.56 | 78.1% | +0.0% | — | $0.4B | 4 |
| Next Q | $-0.42 | $-0.77–$0.11 | 83.6% | +0.0% | — | $0.4B | 4 |
| Current FY | $-6.49 | $-7.38–$-4.91 | 49.0% | +0.0% | — | $1.5B | 4 |
| Next FY | $9.63 | $7.01–$12.84 | 248.3% | +0.0% | 2↑ 1↓ | $2.1B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.087 | — |
| 7d ago | $-1.087 | — |
| 30d ago | $-1.087 | — |
| 60d ago | $-1.033 | -0.054 |
| 90d ago | $-1.033 | -0.054 |
Institutional ownership
Which big funds own MDGL (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $11.1B total value (20,590,230 shares) as of 2026-Q2. Top holders: NOMURA, BAKER, RTW. Net buying activity: 29 institutions added/increased vs 21 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| NOMURA ASSET MANAGEMENT CO LTD | 0 | $0.00 | 0.0% | — |
| BAKER BROS. ADVISORS LP | 2,143,131 | $1.2B | 10.4% | — |
| RTW INVESTMENTS, LP | 1,993,687 | $1.1B | 9.7% | — |
| Jupiter Topco LLC | 1,936,099 | $1.0B | 9.4% | — |
| Avoro Capital Advisors LLC | 1,833,333 | $984.4M | 8.9% | — |
| PAULSON & CO. INC. | 1,340,020 | $719.5M | 6.5% | — |
| BlackRock, Inc. | 1,200,770 | $644.8M | 5.8% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 835,668 | $448.7M | 4.1% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 825,714 | $443.4M | 4.0% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 781,731 | $419.8M | 3.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| UBS Group AG | DOUBLED | 117,779 | 401,708 | +241.1% | $215.7M |
| FMR LLC | TRIM | 511,728 | 356,201 | -30.4% | $191.3M |
| AMERIPRISE FINANCIAL INC | DOUBLED | 98,181 | 231,205 | +135.5% | $124.1M |
| NORGES BANK | NEW | — | 213,886 | — | $114.8M |
| JANE STREET GROUP, LLC | DOUBLED | 35,838 | 191,541 | +434.5% | $102.8M |
| ALLIANCEBERNSTEIN L.P. | ADD | 125,447 | 189,458 | +51.0% | $99.2M |
| TORONTO DOMINION BANK | ADD | 130,460 | 181,432 | +39.1% | $97.4M |
| Hood River Capital Management LLC | TRIM | 249,511 | 169,084 | -32.2% | $90.8M |
| Holocene Advisors, LP | NEW | — | 152,924 | — | $82.1M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | 22,216 | 148,610 | +568.9% | $79.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 50 transactions. Net -$7.9M — $0.00 bought, $7.9M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Sibold William John | President and CEO | SELL | 60 | $533.09 | $32.0K |
| Sep 11, 2026 | Sibold William John | President and CEO | SELL | 218 | $535.94 | $116.8K |
| Sep 11, 2026 | Sibold William John | President and CEO | SELL | 368 | $541.64 | $199.3K |
| Sep 11, 2026 | Sibold William John | President and CEO | SELL | 1,539 | $544.02 | $837.3K |
| Sep 11, 2026 | Sibold William John | President and CEO | SELL | 106 | $534.06 | $56.6K |
| Sep 11, 2026 | Sibold William John | President and CEO | SELL | 1,202 | $542.60 | $652.2K |
| Sep 11, 2026 | Sibold William John | President and CEO | SELL | 160 | $537.62 | $86.0K |
| Sep 11, 2026 | Sibold William John | President and CEO | SELL | 687 | $540.59 | $371.4K |
| Sep 11, 2026 | Sibold William John | President and CEO | SELL | 120 | $546.38 | $65.6K |
| Sep 11, 2026 | Sibold William John | President and CEO | SELL | 761 | $544.83 | $414.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MDGL.
Shares short
2,254,423
Settlement Sep 15, 2026
Change vs prior
+0.6%
Semi-monthly cycle
Days to cover
11.4
At avg daily volume
Of shares outstanding
≈9.8%
Estimate — not % of float
All MDGL filing & press-release reports (9)
- 8-K reportAug 12, 2026
- 8-K reportJul 30, 2026
- CLUSTER reportMay 22, 2026
- 8-K reportMay 6, 2026
- 8-K reportApr 28, 2026
- PRESS-RELEASE reportApr 22, 2026
- PRESS-RELEASE reportMar 19, 2026
- CLUSTER reportMar 6, 2026
- CLUSTER reportMar 6, 2026